JP2014508138A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508138A5
JP2014508138A5 JP2013549850A JP2013549850A JP2014508138A5 JP 2014508138 A5 JP2014508138 A5 JP 2014508138A5 JP 2013549850 A JP2013549850 A JP 2013549850A JP 2013549850 A JP2013549850 A JP 2013549850A JP 2014508138 A5 JP2014508138 A5 JP 2014508138A5
Authority
JP
Japan
Prior art keywords
cells
combination
group
heparin
thrombin inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013549850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508138A (ja
JP6012629B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/051157 external-priority patent/WO2012101181A1/en
Publication of JP2014508138A publication Critical patent/JP2014508138A/ja
Publication of JP2014508138A5 publication Critical patent/JP2014508138A5/ja
Application granted granted Critical
Publication of JP6012629B2 publication Critical patent/JP6012629B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013549850A 2011-01-25 2012-01-25 細胞移植のための組成物および方法 Expired - Fee Related JP6012629B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11152119 2011-01-25
EP11152119.1 2011-01-25
PCT/EP2012/051157 WO2012101181A1 (en) 2011-01-25 2012-01-25 Compositions and methods for cell transplantation

Publications (3)

Publication Number Publication Date
JP2014508138A JP2014508138A (ja) 2014-04-03
JP2014508138A5 true JP2014508138A5 (enExample) 2015-03-12
JP6012629B2 JP6012629B2 (ja) 2016-10-25

Family

ID=45607724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549850A Expired - Fee Related JP6012629B2 (ja) 2011-01-25 2012-01-25 細胞移植のための組成物および方法

Country Status (12)

Country Link
US (3) US20130302291A1 (enExample)
EP (1) EP2667878B1 (enExample)
JP (1) JP6012629B2 (enExample)
CN (1) CN103402527B (enExample)
CA (1) CA2825252C (enExample)
DK (1) DK2667878T3 (enExample)
ES (1) ES2573522T3 (enExample)
IL (1) IL227529A0 (enExample)
PL (1) PL2667878T3 (enExample)
PT (1) PT2667878E (enExample)
SG (1) SG192124A1 (enExample)
WO (1) WO2012101181A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573522T3 (es) 2011-01-25 2016-06-08 Université Catholique de Louvain Composiciones y métodos para el trasplante celular
ES2726802T3 (es) 2012-01-25 2019-10-09 Univ Catholique Louvain Composiciones y métodos para el trasplante celular
EP2943206A4 (en) * 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
SG10201906304TA (en) * 2013-03-15 2019-08-27 Miromatrix Medical Inc Use of perfusion decellularized liver for islet cell recellularization
JP6474394B2 (ja) 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
BR102013033827B1 (pt) * 2013-12-27 2021-09-08 Regenera - Medicina Veterinária Avançada Ltda. Concentrado multipotente e imunocompatível de células-tronco e biofármaco e forma de dosagem que o compreendem
WO2016198578A1 (en) * 2015-06-11 2016-12-15 Universiteit Maastricht Method for preventing transplant failure in a host.
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
EP3591037A4 (en) * 2017-03-03 2020-11-11 Rohto Pharmaceutical Co., Ltd. MESENCHYMATIC STEM CELL AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
KR20200028391A (ko) 2017-06-12 2020-03-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 세포 생착용 패치 이식편 조성물
JP7264589B2 (ja) * 2017-12-25 2023-04-25 株式会社 資生堂 トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤
WO2019241499A1 (en) 2018-06-13 2019-12-19 Miromatrix Medical Inc. Fistula filler and deployment system
CN113677790B (zh) * 2019-03-26 2024-05-24 普罗米瑟拉疗法公司 用于治疗慢加急性肝衰竭的成体肝祖细胞
CN112608890B (zh) * 2020-12-17 2024-08-20 山东佰鸿干细胞生物技术有限公司 一种防止间充质干细胞粘连的培养方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9010552D0 (en) 1990-05-10 1990-07-04 Erba Carlo Spa Method for the recombinant production of hirudins and novel hirudins
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
GB0014136D0 (en) 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
DE10202982A1 (de) 2002-01-26 2003-07-31 Augustinus Bader Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
JP2009508650A (ja) * 2005-09-21 2009-03-05 ダスク テクノロジーズ, エルエルシー 臓器および組織機能のための方法および組成
CA2634510C (en) * 2005-12-21 2018-01-09 Universite Catholique De Louvain Isolated liver stem cells
ES2573522T3 (es) 2011-01-25 2016-06-08 Université Catholique de Louvain Composiciones y métodos para el trasplante celular
ES2726802T3 (es) 2012-01-25 2019-10-09 Univ Catholique Louvain Composiciones y métodos para el trasplante celular

Similar Documents

Publication Publication Date Title
JP2015508054A5 (enExample)
Sang et al. Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis
WO2009033731A3 (en) Use of a laminin peptide as a therapeutic agent
WO2009033774A3 (en) Use of a laminin nonapeptide as a therapeutic agent
Slegtenhorst et al. Mechanisms and consequences of injury and repair in older organ transplants
WO2009043464A3 (en) Astressin and beta- endorphin for use as therapeutic agents
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
EP2996699B1 (en) Salmonella strains for use in the treatment and/or prevention of bladder cancer
BR112014012739A2 (pt) composições e métodos para o tratamento do vírus da hepatite c
WO2009033799A3 (en) Use of a peptide as a therapeutic agent
WO2009033756A3 (en) Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
WO2009033717A3 (en) Use of gonadorelin as a therapeutic agent
WO2009040084A3 (en) Use of a peptide as a therapeutic agent
WO2009033789A3 (en) Use of a peptide as a therapeutic agent
WO2009033747A3 (en) Use of a peptide as a therapeutic agent
Tombor et al. Why is endothelial resilience key to maintain cardiac health?
WO2009049742A3 (en) Use of melanotrophin-potentiating factor as a therapeutic agent
WO2009040028A3 (en) Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis
WO2009040035A3 (en) Use of a peptide as a therapeutic agent
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
WO2009043449A3 (en) Use of a peptide as a therapeutic agent
WO2009040033A3 (en) Use of a peptide as a therapeutic agent
WO2009033748A3 (en) Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same